Lexicon Pharma Initiates Dosing in Biliary Tract Cancer Study

Lexicon Pharmaceuticals, Inc. LXRX announced that it has dosed the first patient in a phase IIa study — TELE-ABC — evaluating its sole marketed drug, Xermelo (telotristat ethyl), in patients with biliary tract cancer.